HeartBeam has received FDA clearance for its synthesized 12-lead ECG software, making it the first cable-free device of its kind for at-home arrhythmia assessment. The clearance followed a successful ...
Twelve-lead ECGs, although standard in hospitals, can be bulky and impractical for home use. On the other hand, Apple Watch’s ECG app is easy to use, but it is limited in what it can detect because it ...
FDA Clearance Granted After Successful Appeal, Overturning Prior Not Substantially Equivalent (NSE) Outcome HeartBeam’s Credit-Card Sized Device Delivers Clinical-Grade Insights Directly to Patients ...
HeartBeam (NASDAQ: BEAT) announced a strategic collaboration with the Icahn School of Medicine at Mount Sinai in New ...
(NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful cardiac insights, announced a commercial partnership with ClearCardio (TM), a leading preventive ...
HeartBeam Inc. (NASDAQ:BEAT) saw its stock soar 52.6% in premarket trading Wednesday after the company announced that the FDA has granted 510(k) clearance for its 12-lead electrocardiogram (ECG) ...
HeartBeam CEO Robert Eno and CFO Timothy Cruickshank will attend the virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference on March 16-17, 2026. Management will host a presentation ...
An investigation has found a "concerning level of variation" in how 12-lead electrocardiogram (ECG) skills are taught in UK undergraduate paramedic programmes. A report by the Health Services Safety ...
HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care by providing powerful personalized insights, today announced that the U.S. Food and Drug ...
(RTTNews) - HeartBeam, Inc. (BEAT), a medical technology company, announced Wednesday that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for the Company's groundbreaking ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results